BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung CancerGlobeNewsWire • 03/24/26
BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewsWire • 03/10/26
BioNTech co-founders set to launch new mRNA venture as company sharpens oncology focusProactive Investors • 03/10/26
BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.Barrons • 03/10/26
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate UpdateGlobeNewsWire • 03/10/26
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030GlobeNewsWire • 03/10/26
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026GlobeNewsWire • 02/24/26
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People OfficerGlobeNewsWire • 01/28/26
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/22/26
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/12/26
University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences FundBusiness Wire • 01/09/26
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA FieldGlobeNewsWire • 12/18/25